BeiGene stock reports 30 percent revenue growth

BeiGene stock was trading at USD 357.26 on Nasdaq on September 24, 2026, down 2.12 percent for the session. As ScanX reported on September 17, 2026, Q2 revenue increased 30 percent year over year to USD 1.7 billion.

Q2 revenue reaches USD 1.7 billion

The result included GAAP earnings of USD 2.05 per ADS, up 144 percent year over year, while net income reached USD 237 million. The comparison gives the quarterly result more weight than the revenue figure alone because earnings growth outpaced sales growth.

Free cash flow doubled year over year to USD 435 million in Q2 2026, according to ScanX. Operating income reached USD 325 million, while gross profit stood at USD 1.5 billion.

Brukinsa drives the mix

Brukinsa generated more than USD 1.2 billion in global revenue in Q2 2026, up 31 percent year over year. That figure represents more than 70 percent of the USD 1.7 billion quarterly total, leaving the drug as the central driver of both growth and revenue concentration.

Management raised full-year 2026 revenue guidance to USD 6.6 billion to USD 6.8 billion and lifted GAAP operating income guidance to USD 1.0 billion to USD 1.1 billion, according to ScanX. The higher outlook places execution on Brukinsa and the expanding product portfolio at the center of the next reporting periods.

Nasdaq quote stays below yearly high

BeiGene stock had a market capitalization of USD 38,176,257,707 on September 24, 2026. Its 52-week range was USD 253.95 to USD 385.22, putting the current quote 7.26 percent below the yearly high.

The company now trades under the ONC ticker on Nasdaq as BeOne Medicines AG, while the Q2 results continue to be reported under the BeiGene name in the cited financial coverage. The combination of 30 percent revenue growth, a 144 percent increase in GAAP earnings per ADS and higher annual guidance defines the current investment narrative.